Who owns Kodiak Sciences Inc. (KOD)? Elite investor 13F holders

3 tracked elite investors reported holding Kodiak Sciences Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCKODIAK SCIENCES INCSHARE2026-06-302026-08-13 00:00:007371232.00 USD189200.000000SharesreduceOriginal filing
D.E. ShawKODIAK SCIENCES INCSHARE2026-06-302026-08-14 00:00:008232248.00 USD211300.000000SharesreduceOriginal filing
Polen Capital ManagementKODIAK SCIENCES INCSHARE2026-06-302026-08-04 00:00:001381872.00 USD35469.000000SharesreduceOriginal filing
Tudor InvestmentKODIAK SCIENCES INCSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown